Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)

Valentina Alari; Silvia Russo; Davide Rovina; Aoife Gowran; Maria Garzo; Milena Crippa; Laura Mazzanti; Claudia Scalera; Ennio Prosperi; Daniela Giardino; Cristina Gervasini; Palma Finelli; Giulio Pompilio; Lidia Larizza

doi:10.1016/j.scr.2018.06.009

Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)

Valentina Alari, Silvia Russo, Davide Rovina, Aoife Gowran, Maria Garzo, Milena Crippa, Laura Mazzanti, Claudia Scalera, Ennio Prosperi, Daniela Giardino, Cristina Gervasini, Palma Finelli, Giulio Pompilio, Lidia Larizza

Research output: Contribution to journal › Article › peer-review

Abstract

Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused by heterozygous mutation in either the CREBBP (RSTS1) or EP300 (RSTS2) genes. We generated an induced pluripotent stem cell line from an RSTS2 patient's blood mononuclear cells by Sendai virus non integrative reprogramming method. The iPSC line (IAIi001RSTS2-65-A) displayed iPSC morphology, expressed pluripotency markers, possessed trilineage differentiation potential and was stable by karyotyping. Mutation and western blot analyses demonstrated in IAIi001RSTS2-65-A the patient's specific non sense mutation in exon 23 c.3829A > T, p.(Lys 1277*) and showed reduced quantity of wild type p300 protein.

Original language	English
Pages (from-to)	175-179
Number of pages	5
Journal	Stem Cell Research
Volume	30
DOIs	https://doi.org/10.1016/j.scr.2018.06.009
Publication status	Published - Jul 1 2018

ASJC Scopus subject areas

Developmental Biology
Cell Biology

Access to Document

10.1016/j.scr.2018.06.009

Cite this

Alari, V., Russo, S., Rovina, D., Gowran, A., Garzo, M., Crippa, M., Mazzanti, L., Scalera, C., Prosperi, E., Giardino, D., Gervasini, C., Finelli, P., Pompilio, G., & Larizza, L. (2018). Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*). Stem Cell Research, 30, 175-179. https://doi.org/10.1016/j.scr.2018.06.009

Alari, V , Russo, S , Rovina, D , Gowran, A, Garzo, M, Crippa, M, Mazzanti, L, Scalera, C, Prosperi, E, Giardino, D, Gervasini, C, Finelli, P , Pompilio, G & Larizza, L 2018, 'Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)', Stem Cell Research, vol. 30, pp. 175-179. https://doi.org/10.1016/j.scr.2018.06.009

@article{e9eaf9ed1e2745ee9f418d4d72f0e453,

title = "Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)",

abstract = "Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused by heterozygous mutation in either the CREBBP (RSTS1) or EP300 (RSTS2) genes. We generated an induced pluripotent stem cell line from an RSTS2 patient's blood mononuclear cells by Sendai virus non integrative reprogramming method. The iPSC line (IAIi001RSTS2-65-A) displayed iPSC morphology, expressed pluripotency markers, possessed trilineage differentiation potential and was stable by karyotyping. Mutation and western blot analyses demonstrated in IAIi001RSTS2-65-A the patient's specific non sense mutation in exon 23 c.3829A > T, p.(Lys 1277*) and showed reduced quantity of wild type p300 protein.",

author = "Valentina Alari and Silvia Russo and Davide Rovina and Aoife Gowran and Maria Garzo and Milena Crippa and Laura Mazzanti and Claudia Scalera and Ennio Prosperi and Daniela Giardino and Cristina Gervasini and Palma Finelli and Giulio Pompilio and Lidia Larizza",

year = "2018",

month = jul,

day = "1",

doi = "10.1016/j.scr.2018.06.009",

language = "English",

volume = "30",

pages = "175--179",

journal = "Stem Cell Research",

issn = "1873-5061",

publisher = "Elsevier",

}

TY - JOUR

T1 - Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)

AU - Alari, Valentina

AU - Russo, Silvia

AU - Rovina, Davide

AU - Gowran, Aoife

AU - Garzo, Maria

AU - Crippa, Milena

AU - Mazzanti, Laura

AU - Scalera, Claudia

AU - Prosperi, Ennio

AU - Giardino, Daniela

AU - Gervasini, Cristina

AU - Finelli, Palma

AU - Pompilio, Giulio

AU - Larizza, Lidia

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused by heterozygous mutation in either the CREBBP (RSTS1) or EP300 (RSTS2) genes. We generated an induced pluripotent stem cell line from an RSTS2 patient's blood mononuclear cells by Sendai virus non integrative reprogramming method. The iPSC line (IAIi001RSTS2-65-A) displayed iPSC morphology, expressed pluripotency markers, possessed trilineage differentiation potential and was stable by karyotyping. Mutation and western blot analyses demonstrated in IAIi001RSTS2-65-A the patient's specific non sense mutation in exon 23 c.3829A > T, p.(Lys 1277*) and showed reduced quantity of wild type p300 protein.

AB - Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused by heterozygous mutation in either the CREBBP (RSTS1) or EP300 (RSTS2) genes. We generated an induced pluripotent stem cell line from an RSTS2 patient's blood mononuclear cells by Sendai virus non integrative reprogramming method. The iPSC line (IAIi001RSTS2-65-A) displayed iPSC morphology, expressed pluripotency markers, possessed trilineage differentiation potential and was stable by karyotyping. Mutation and western blot analyses demonstrated in IAIi001RSTS2-65-A the patient's specific non sense mutation in exon 23 c.3829A > T, p.(Lys 1277*) and showed reduced quantity of wild type p300 protein.

UR - http://www.scopus.com/inward/record.url?scp=85048979530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048979530&partnerID=8YFLogxK

U2 - 10.1016/j.scr.2018.06.009

DO - 10.1016/j.scr.2018.06.009

M3 - Article

AN - SCOPUS:85048979530

VL - 30

SP - 175

EP - 179

JO - Stem Cell Research

JF - Stem Cell Research

SN - 1873-5061

ER -

Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this

Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this

Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*)